Tissue Regeneration Systems (TRS) is a start-up medical device company commercializing a breakthrough skeletal reconstruction and bone regeneration technology platform licensed from the Universities of Michigan and Wisconsin. Our technology has been evaluated in several large animal studies with very promising long term results. We have conceptualized initial product offerings, completed all required bench and animal testing, and filed our first regulatory submissions to the FDA. Approval of these submissions will allow TRS to commercialize products in the United States and we expect to begin generating meaningful revenues in the next two to three years.